secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001193125-24-067966
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio shareholders approve all merger-related proposals for Lenz deal
----------------------------------------------------------------------------

- Proposal 1 (stock issuance and control change) passed: 40.9M for, 37k against, 7.5M broker non-votes.
- Proposal 2 (reverse split 1:6–1:12 and name change to LENZ Therapeutics) passed: 48.3M for, 170k against.
- Proposal 3 (2024 Equity Incentive Plan) passed: 36.6M for, 4.4M against, 7.5M broker non-votes.
- Proposal 4 (2024 Employee Stock Purchase Plan) passed: 37.3M for, 3.7M against, 7.5M broker non-votes.
- Proposal 5 (adjournment) not presented; sufficient votes existed for Proposals 1 and 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000119312524067966/0001193125-24-067966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000119312524067966/d788095d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-067966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer